Barbara Merriman, DO
Neurology · Rapid City, SDNPI 1295173656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,391 and has fallen 98.6% since, to $19 in 2022.
Across 120 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$333
- Novartis$305
- EMD Serono, Inc.$131
- Amgen$110
- AstraZeneca$109
- Amneal Pharmaceuticals LLC$97
- plus $869 from 21 others
What the payments were for
- Food & beverage$1,951100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $333 |
| Novartis | 24 | $305 |
| EMD Serono, Inc. | 6 | $131 |
| Amgen | 6 | $110 |
| AstraZeneca | 8 | $109 |
| Amneal Pharmaceuticals LLC | 6 | $97 |
| UCB, Inc. | 6 | $89 |
| Medtronic | 1 | $86 |
| Biogen | 6 | $79 |
| Sanofi | 5 | $73 |
| CSL Behring | 4 | $70 |
| Acadia Pharmaceuticals Inc | 5 | $67 |
| Genentech USA, Inc. | 4 | $63 |
| Grifols USA, LLC | 4 | $56 |
| Lilly USA, LLC | 3 | $42 |
| Lundbeck LLC | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Travere Therapeutics, Inc. | 4 | $23 |
| Aquestive Therapeutics, Inc. | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Greenwich Biosciences, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Livanova USA, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$1,953 in reported general payments places this provider in the 65th percentile of 49 neurology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 99 | $1,083 |
| Pregabalin | 29 | $653 |
| Duloxetine Hcl | 46 | $299 |
| Memantine Hcl | 17 | $151 |
| Topiramate | 21 | $148 |
| Atorvastatin Calcium | 16 | $45 |
| Lorazepam | 36 | $25 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rapid City
- Jennifer KrugerRapid City$19K
- Mohamadmostafa JahansouzRapid City$3K
- Lee McCraneyRapid City$2K
- Heather CwachRapid City$2K
- Brian TschidaRapid City$1K
- Robert FinleyRapid City$732
- Eunhye OakRapid City$429
- Steven HataRapid City$407
- Matthew SimmonsRapid City$250
- Robert MaclachlanRapid City$163
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.